Horizon Therapeutics plc Announces Phase II Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics plc announced that its Phase II trial evaluating dazodalibep for the treatment of Sjögren’s syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity as defined by the European Alliance of Associations for Rheumatology Sjögren’s Syndrome Disease Activity Index score of equal to or higher than 5.